StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Rajesh Palviya, Axis Securities

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Swing (≤2wk))30 Jul 2026via Business Today

Entry₹2,270.2Inferred
Target₹2,350
Total upside +3.52% (call closed)
Stop loss₹2,220-2.21% risk
Exit₹2,22030 Jul 2026, 12:25 pm
Stop-loss hit-2.21%
Follow Rajesh Palviya for new calls(27% target hit, 183 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 2 active Swing calls on GLENMARKSee 142 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Jul 2026
5 supporting0 opposing
Supports the BUY call (5)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·30 Jul · today

Glenmark Pharmaceuticals Inc., USA has launched Sugammadex Injection in single-dose vials, available in 200 mg/2mL and 500 mg/5mL strengths.

BSE · Company Update·28 Jul · yesterday

(opens in new tab)

Glenmark Pharma gets USFDA nod to expand RYALTRIS use to children aged 6-12

NewsCnbc-Tv18·21 Jul · 1w ago

(opens in new tab)

Glenmark Pharmaceuticals Ltd has received approval from the U.S. FDA to expand the use of its RYALTRIS Nasal Spray to include children aged 6 to less than 12 years.

BSE · Company Update·21 Jul · 1w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·7 Jul · 3w ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Rajesh Palviya, Axis Securities

Every call and its outcome